- Joined
- Jul 10, 2014
- Messages
- 17,925
- Reaction score
- 30,053
- Points
- 113
[h=1]COVID-19 Survivors Have Broad, Longer-Term Immunity[/h]
https://www.cell.com/cell-reports-m...m/retrieve/pii/S2666379121002032?showall=true
[h=1]Longer-Term Immunity[/h] By Rajee Suri
August 7, 2021 Updated: August 7, 2021
biggersmaller Print
People who have recovered from COVID-19 retain broad and effective longer-term immunity to the disease, according to a new study.
Findings of the study, which is the most comprehensive of its kind so far, have implications for expanding understanding about human immune memory as well as future vaccine development for coronaviruses.
For the longitudinal study in Cell Reports Medicine, researchers looked at 254 patients with mostly mild to moderate symptoms of SARS-CoV-2 infection over a period of more than eight months (250 days) and found that their immune response to the virus remained durable and strong.
The findings are reassuring, especially given early reports during the pandemic that protective neutralizing antibodies didn’t last in COVID-19 patients, said Rafi Ahmed, director of the Emory University Vaccine Center and a lead author of the paper.
“The study serves as a framework to define and predict long-lived immunity to SARS-CoV-2 after natural infection. We also saw indications in this phase that natural immunity could continue to persist,” Ahmed said.
https://www.cell.com/cell-reports-m...m/retrieve/pii/S2666379121002032?showall=true
[h=1]Longer-Term Immunity[/h] By Rajee Suri
August 7, 2021 Updated: August 7, 2021
biggersmaller Print
People who have recovered from COVID-19 retain broad and effective longer-term immunity to the disease, according to a new study.
Findings of the study, which is the most comprehensive of its kind so far, have implications for expanding understanding about human immune memory as well as future vaccine development for coronaviruses.
For the longitudinal study in Cell Reports Medicine, researchers looked at 254 patients with mostly mild to moderate symptoms of SARS-CoV-2 infection over a period of more than eight months (250 days) and found that their immune response to the virus remained durable and strong.
The findings are reassuring, especially given early reports during the pandemic that protective neutralizing antibodies didn’t last in COVID-19 patients, said Rafi Ahmed, director of the Emory University Vaccine Center and a lead author of the paper.
“The study serves as a framework to define and predict long-lived immunity to SARS-CoV-2 after natural infection. We also saw indications in this phase that natural immunity could continue to persist,” Ahmed said.